| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.6M | -14.3% | -42.4% |
| SG&A Expense | $1.5M | -7.1% | -7.8% |
| Operating Income | -$3.1M | +8.0% | +23.9% |
| Income Tax | $0 | — | — |
| Net Income | -$3.0M | +8.2% | +21.4% |
| EPS (Basic) | -$0.47 | +11.3% | +26.6% |
| EPS (Diluted) | -$0.47 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $13.7M | -17.0% | -47.7% |
| Current Assets | $13.9M | -17.6% | -47.3% |
| Total Assets | $14.3M | -17.3% | -46.7% |
| Current Liabilities | $2.7M | -15.4% | -26.3% |
| Stockholders' Equity | $10.9M | -18.6% | -50.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.9M | — | — |
| Capital Expenditures | $15K | — | — |
| Investing Cash Flow | -$15K | — | — |
| Financing Cash Flow | $799K | — | — |
| Free Cash Flow | -$9.9M | — | — |
| +26.6% |